Matthew A Movsesian
Physician in Salt Lake City, UT
License number
Utah 175710-1205
Issued Date
Sep 22, 1986
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician & Surgeon
Address
Address
Salt Lake City, UT
Personal information
See more information about Matthew A Movsesian at radaris.comName
Address
Phone
S Salt Lake, UT
151 4Th Ave, Salt Lake City, UT 84103
151 4Th Ave, Salt Lake Cty, UT 84103
Organization information
See more information about Matthew A Movsesian at bizstanding.comMatthew Movsesian MD
30 N 1900 E, Salt Lake City, UT 84132
Industry:
Internist
Phone:
(801) 581-7715 (Phone)
Matthew Arthur Movsesian
Professional information
Professor, Internal Medicine (Cardiology) And Pharmacology At University Of Utah School Of Medicine
Position:
Founder at Fourth West Bioscience, Professor, Internal Medicine (Cardiology) and Pharmacology at University of Utah School of Medicine
Location:
Salt Lake City, Utah
Industry:
Research
Work:
Fourth West Bioscience
- Greater Salt Lake City Area since 2009
-
Founder
University of Utah School of Medicine
- Greater Salt Lake City Area since 1986
-
Professor, Internal Medicine (Cardiology) and Pharmacology
VA Salt Lake City Health Care System
- Greater Salt Lake City Area Jan 2002 - Aug 2009
-
Chief, Cardiology Section
UCSF Medical Center
- San Francisco Bay Area 1984 - 1986
-
Fellow, cardiovascular diseases
National Institutes of Health
- Bethesda, MD 1981 - 1984
-
Postdoctoral fellow, molecular biology
Northwestern University, Feinberg School of Medicine
- Chicago, IL 1978 - 1981
-
Resident, internal medicine
Education:
Harvard Medical School 1974 - 1978
Doctor of Medicine (MD) Columbia University in the City of New York 1971 - 1974
AB, Chemistry
Doctor of Medicine (MD) Columbia University in the City of New York 1971 - 1974
AB, Chemistry
Languages:
French, German
Isoform-Selective Inhibitors And Activators Of Pde3 Cyclic Nucleotide Phosphodiesterases
US Patent:
2003015, Aug 21, 2003
Filed:
Jun 19, 2002
Appl. No.:
10/175161
Inventors:
Matthew Movsesian - Salt Lake City UT, US
International Classification:
A61K048/00, C12Q001/68, C07H021/04, C12N009/16, C12P021/02, C12N005/06
US Classification:
514/044000, 435/006000, 435/069100, 435/196000, 435/320100, 435/325000, 536/023200
Abstract:
The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
Isoform-Selective Inhibitor And Activators Of Pde3 Cyclic Nucleotide Phosphodiesterases
US Patent:
2010026, Oct 21, 2010
Filed:
Jan 18, 2007
Appl. No.:
11/654858
Inventors:
Matthew A. Movsesian - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
Pde1 As A Target Therapeutic In Heart Disease
US Patent:
2012007, Mar 22, 2012
Filed:
Dec 2, 2009
Appl. No.:
13/132547
Inventors:
Matthew Movsesian - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61K 39/395, A61K 31/7088, A61K 38/02, A61P 9/00, A61P 9/04, C07K 16/40, C12Q 1/44, C40B 30/08, C07K 14/00, C07H 21/00, C07H 21/02, A61K 31/713, A61P 9/06
US Classification:
4241581, 514 44 A, 514 44 R, 514 164, 435 19, 506 11, 530350, 536 231, 536 245, 5303898
Abstract:
Disclosed are compositions and methods related to inhibition of PDE1.